Epirus Biopharmaceuticals (EPRS) and Its Peers Head-To-Head Contrast
Epirus Biopharmaceuticals (NASDAQ: EPRS) is one of 95 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Epirus Biopharmaceuticals to related companies based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Risk & Volatility
Epirus Biopharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500. Comparatively, Epirus Biopharmaceuticals’ peers have a beta of 1.13, indicating that their average stock price is 13% more volatile than the S&P 500.
20.3% of shares of all “Biotechnology” companies are held by institutional investors. 19.6% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Epirus Biopharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Epirus Biopharmaceuticals Competitors||-910.58%||-183.99%||-27.07%|
This is a summary of current recommendations and price targets for Epirus Biopharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Epirus Biopharmaceuticals Competitors||123||467||1168||11||2.60|
As a group, “Biotechnology” companies have a potential upside of 69.24%. Given Epirus Biopharmaceuticals’ peers higher possible upside, analysts plainly believe Epirus Biopharmaceuticals has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Epirus Biopharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Epirus Biopharmaceuticals Competitors||$224.58 million||$57.96 million||-1.18|
Epirus Biopharmaceuticals’ peers have higher revenue and earnings than Epirus Biopharmaceuticals. Epirus Biopharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Epirus Biopharmaceuticals peers beat Epirus Biopharmaceuticals on 7 of the 8 factors compared.
About Epirus Biopharmaceuticals
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.